Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €49.33 EUR
Change Today -0.71 / -1.41%
Volume 0.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 10:37 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for alkermes plc (8AK)

Although debt as a percent of total capital decreased at Alkermes plc over the last fiscal year to 20.40%, it is still in-line with the Biotechnology industry's norm. Additionally, there are enough liquid assets to satisfy current obligations. Accounts Receivable are typical for the industry, with 84.26 days worth of sales outstanding. Last, inventories seem to be well managed as the Inventory Processing Period is typical for the industry, at 101.28 days.
Currency in
Millions of US Dollars
As of:Mar 31
2011
Reclassified
Mar 31
2012
Reclassified
Dec 31
2013
Dec 31
2014
4 Year
Trend
Assets    
Cash and Equivalents38.483.6167.6224.1
Short-Term Investments162.9106.8194.7407.1
TOTAL CASH AND SHORT TERM INVESTMENTS201.3190.4362.2631.2
Accounts Receivable23.096.4134.2151.6
TOTAL RECEIVABLES23.096.4134.2151.6
Inventory20.439.846.251.4
Prepaid Expenses8.212.614.628.0
Deferred Tax Assets, Current----12.813.4
Other Current Assets----0.21.3
TOTAL CURRENT ASSETS253.0339.2570.1876.8
Gross Property Plant and Equipment186.7416.3428.1435.9
Accumulated Depreciation-91.7-113.3-153.6-170.2
NET PROPERTY PLANT AND EQUIPMENT95.0303.0274.5265.7
Goodwill--92.792.794.2
Long-Term Investments103.266.489.8171.7
Deferred Charges, Long Term----1.48.8
Other Intangibles--617.8537.6479.4
Other Long-Term Assets1.316.111.524.6
TOTAL ASSETS452.41,435.21,577.61,921.3
    
LIABILITIES & EQUITY    
Accounts Payable9.318.419.532.3
Accrued Expenses35.760.864.486.9
Current Portion of Long-Term Debt/Capital Lease--3.16.86.8
Other Current Liabilities, Total----7.32.0
Unearned Revenue, Current3.16.93.02.6
TOTAL CURRENT LIABILITIES48.189.2100.9130.6
Long-Term Debt--441.9357.8351.2
Unearned Revenue, Non-Current4.87.612.211.8
Deferred Tax Liability Non-Current--34.529.218.9
Other Non-Current Liabilities7.58.212.311.9
TOTAL LIABILITIES60.4581.4512.4524.4
Common Stock1.11.31.41.5
Additional Paid in Capital936.31,380.71,553.31,942.9
Retained Earnings-411.2-524.9-482.3-512.3
Treasury Stock-131.1-0.6-17.8-32.1
Comprehensive Income and Other-3.0-2.710.6-3.1
TOTAL COMMON EQUITY392.0853.91,065.21,396.8
TOTAL EQUITY392.0853.91,065.21,396.8
TOTAL LIABILITIES AND EQUITY452.41,435.21,577.61,921.3
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €49.33 EUR -0.71

8AK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $23.71 USD +0.35
Emergent Biosolutions Inc $31.08 USD +0.45
Impax Laboratories Inc $45.00 USD -0.53
Jazz Pharmaceuticals PLC $176.81 USD +0.39
Pacira Pharmaceuticals Inc/DE $67.37 USD +1.59
View Industry Companies
 

Industry Analysis

8AK

Industry Average

Valuation 8AK Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 13.1x
Price/Book 6.0x
Price/Cash Flow 350.5x
TEV/Sales 11.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.